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Background – Feline allergic skin disease and asthma occur regularly in small animal practice.
Objectives – To provide evidence-based recommendations for small animal practitioners on the treatment of
feline atopic syndrome (FAS).
Methods and materials – The authors reviewed the literature available before February 2020, prepared a detai-
led evidence-based literature review and made recommendations based on the evaluated evidence.
Results – Sixty-six papers and abstracts were identified describing treatment interventions for FAS and eva-
luated to establish treatment recommendations. For many treatment options, the papers were retrospective,
open studies or case reports.
Conclusion and clinical relevance – In this review, there was good evidence for the efficacy of systemic gluco-
corticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergen-
specific immunotherapy in feline atopic skin syndrome. Evidence pointed to low-to-moderate efficacy for antihis-
tamines, fatty acids and palmitoyl ethanolamide. In feline asthma, there was good evidence for the efficacy of
oral and inhaled glucocorticoids, and limited evidence of moderate efficacy for allergen-specific immunotherapy.
Evidence supported low-to-moderate efficacy of mesenchymal stem cells, inhaled lidocaine and oclacitinib as
treatments for feline asthma. For almost all therapeutic options (with the exception of glucocorticoids and ciclos-
porin), more randomised controlled trials are needed.
Introduction
Feline atopic syndrome (FAS) is the newly-proposed ter-
minology encompassing allergic diseases of the skin,
gastrointestinal and respiratory tract in the cat. Feline ato-
pic skin syndrome (FASS) describes allergic skin disease
associated with environmental allergies.1–3 Allergic der-
matitis in the cat presents with multiple cutaneous reac-
tion patterns that all may be caused by environmental,
food and/or insect allergens, as well as other diseases.
Those reaction patterns include miliary dermatitis, self-in-
duced alopecia/hypotrichosis, the eosinophilic granuloma
complex (eosinophilic granuloma, eosinophilic plaque,
indolent ulcer) and/or excoriations-ulcers on the head and
neck.3 Consequently, the treatment of these reaction
patterns will depend on their aetiology, and other causes
such as food allergy or flea bite hypersensitivity must be
ruled out before diagnosing FASS. Feline asthma is a
common lower airway inflammatory condition in cats
with significant morbidity and occasional mortality. From
a clinical and pathogenetic point of view, feline asthma is
remarkably similar to the human disease. As in humans,
affected cats exhibit a spontaneous and natural hyper-re-
activity of the airways resulting in a reversible bron-
choconstriction, airway inflammation and chronic
remodelling.4 Intradermal and serum testing for allergen-
specific immunoglobulin (Ig)E is not suitable for the diag-
nosis of FAS. Similar to dogs, the FASS is diagnosed
based on the history, clinical signs and exclusion of dif-
ferential diagnoses appropriate to each case.5 Over the
last decades, different treatments have been reported
for FAS variants, yet to the best of the authors’ knowl-
edge, a systematic review of all available therapeutic and
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preventive interventions has not been published. The aim
of this review was therefore to summarise and review
the published evidence for the various treatment options
for the cutaneous and respiratory components of FAS. It
was not within the remit of this paper to discuss the aeti-
ology, pathogenesis and diagnosis of these diseases.
These subjects are reviewed in other papers in this series
and readers are directed to them for more information.1–3
Methods and materials
In order to evaluate the efficacy and safety of treatments for the two
main FAS manifestations (FASS and asthma), online bibliographic
databases (PUBMED and WEB OF SCIENCE) and scientific meeting
proceedings were searched for relevant published studies or
abstracts of sufficient detail for analysis. The bibliographies of identi-
fied studies and of main veterinary dermatology textbooks were fur-
ther evaluated. Studies were analysed and their value determined
based on the quality of their evidence (QOE). They were summarised
and, based on the available data, a given treatment’s efficacy was
determined and its reported adverse effects listed. Thereafter a rec-
ommendation about each treatment option was given, with the
strength of recommendation (SOR) based on the QOE (Table 1).
Data evaluation and strength of recommendations were modelled
after previous practice guidelines for human6,7 and canine atopic der-
matitis (cAD).8
Results
We found a total of 72 papers and abstracts describing
treatment interventions for FAS. These included 58 clini-
cal trials and eight case reports evaluating efficacy of
treatments,9–16 five safety and pharmacokinetic studies
in healthy cats,17–21 and one retrospective safety study
(without reporting efficacy).22 Of the 55 clinical trials, six
were available only as abstracts23–28 and 49 had been
published in peer-reviewed journals. There were 48
prospective and 10 retrospective studies.23,25,27,29–35 Of
the prospective studies, 19 were open and uncon-
trolled24,28,36–52 while 29 were randomised, controlled53–
59 and often blinded.26,42,60–79 These studies included
clinical trials on allergen avoidance, allergen(-specific)
immunotherapy (ASIT), topical, inhaled and systemic glu-
cocorticoids, ciclosporin, oclacitinib, bronchodilators, H1-
receptor (H1R) antihistamines, essential fatty acids (EFA)
and palmytoylethanolamide, antibiotics, inhaled lidocaine
and mesenchymal stem cells. Thirty-three of the reports
focused on the reaction patterns of FASS, while 23 stud-
ies evaluated feline asthma. Eleven of those latter studies
originated from the same research group using cats
experimentally sensitised to various allergens and five
from another colony of cats sensitised to Ascaris suum.




In one retrospective study of 29 asthmatic cats35 and one
prospective study on 20 asthmatic cats,47 avoidance of
allergens was reported for individual cases. We could not
find any such evidence for FASS.
Analysis of efficacy
In the above-mentioned studies, one cat sensitised to
human dander improved after access to the owner’s bed-
room was restricted.35 Changing from dry food to a moist
diet led to the complete remission of clinical signs in three
cats allergic to storage mites.47
Recommendations
Although allergen avoidance is common sense and
should be effective (QOE 3; SOR C), it is often unfeasible
in cats sensitised to environmental allergens. There is
only limited evidence for the benefit of allergen avoidance




Eleven reports evaluated ASIT in a total of 197 cats with
FASS.12,13,15,16,23,25,28–32 Five retrospective studies
specifically evaluated ASIT in 70 cats with different reac-
tion patterns of FASS.23,25,30,32 Seventeen cats had mil-
iary dermatitis, 21 had noninflammatory alopecia, 18 had
eosinophilic lesions16,25,30,32 and in one study the clinical
signs were not detailed.23 Two of these reports were
abstracts in proceedings from World Congresses of
Veterinary Dermatology and thus not sufficiently
detailed.23,25 Likewise, one prospective open study evalu-
ating sublingual ASIT was a conference abstract.28 One
report described the response to ASIT in three littermates
with atopic skin disease,12 one case series described four
cats with miliary dermatitis and eosinophilic granuloma,16
and another focused on rush immunotherapy (RIT) in four
atopic cats,13 although treatment outcomes were not
described in the latter report. One larger study was based
on a questionnaire sent out by a laboratory after serum
testing for allergen-specific IgE and subsequent orders
for ASIT in 81 cats, six of which had lower respiratory
tract disease.29 The last study evaluated 45 cats with
FASS, 23 of which underwent AIT.31 Definitions of a
good, moderate, partial or no response varied and often
were unclear. In one study, an excellent response was
described as complete remission of the patient with no
concurrent medication and was seen in 26% of the
Table 1. Strength of recommendation taxonomy (SORT)
Strength of recommendation (SOR)
A Based on consistent and good quality patient-orientated evidence
B Based on inconsistent or limited quality patient-orientated evidence
C Based on consensus, usual practice, opinion, disease-orientated evidence or case series
Quality of evidence (QOE)
1 Good quality, patient-orientated
2 Limited quality, patient-orientated
3 Other evidence (usual practice, opinion, or disease-orientated evidence)
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cats.23 In the study using a survey sent out to veterinari-
ans treating cats with ASIT after serum testing for aller-
gen-specific IgE, lesional scores were assigned and the
percentage of improvement calculated.29 In another
study, concurrent medications were not discussed;32 in
many reports concurrent medications were mentioned
and details not given.
Five studies evaluated cats with respiratory disease/
asthma. In an older retrospective study, veteriarians
submitting feline serum specimens for allergen-specific
IgE testing were asked to complete a follow-up ques-
tionnaire, six cats with respiratory clinical signs under-
going ASIT were included.29 One study focussed on
ASIT as treatment for 12 asthmatic cats showing
sensitization to aeroallergens based on intradermal test-
ing.47 Three studies were performed in an experimental
model of feline asthma in which cats were sensitised
to Bermuda grass and house dust mites.59,65,76 In the
first randomised controlled trial (RCT), intranasal or sub-
cutaneous RIT were compared.59 In a second study
using the same model, cats received RIT with an aller-
gen that they were not sensitised to or with only one
of the two allergens they were sensitised to.76 The
third study evaluated the influence of oral and inhaled
glucocorticoids on the outcome of RIT.65 In one confer-
ence abstract, a cat with cutaneous and respiratory sign
was treated with ASIT using a recombinant Der f 2-
based vaccine.15
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1 mL every four
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Good in 10 cats Poor in 5 cats Reedy 198232
Case series
2
Mean outcomes 60% 20% 20%
QOE quality of evidence, RCT randomised controlled trial, ReS retrospective study, SCORFAD Scoring Feline Allergic Dermatitis.
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Analysis of efficacy
The results of ASIT for FASS were reported in 210 cats
(Table 2). The reported efficacy was between 45 and
75%, similar to what is reported for dogs.80,81 One of the
studies did not evaluate treatment outcome, and looked
only at the safety of RIT in four cats with FASS.13
Results of ASIT in 80 cats with asthma are listed in
Table 3. In one study a complete remission of clinical
signs was observed in eight of 12 cats with naturally
occurring asthma (67%) in which symptomatic therapy
with glucocorticoids could be discontinued on ASIT. Four
cats still required pharmacotherapy, including inhaled cor-
ticosteroids and bronchodilators.47 In a retrospective
study, veterinarians treating 12 cats with suspected feline
asthma reported a good response via questionnaire.29
Three studies evaluated ASIT in cats with experimen-
tally induced asthma.59,65,76 In the first RCT, intranasal or
subcutaneous RIT improved clinical signs and dampened
eosinophilic inflammation of the airways.59 However,
intranasal RIT had fewer adverse effects and a decreased
interleukin (IL)-4/interferon-gamma ratio in the bron-
choalveolar lavage fluid (BALF).59 In the second study, air-
way eosinophilia decreased and the percentage of
regulatory T cells and IL-10-producing cells increased in
cats treated with RIT compared to controls independent
of their sensitisation status and content of the allergen
extract, indicating nonspecific effects. However, only
matched allergens could potentially induce an immuno-
logical cure.76 In the same model of feline asthma, cats
given oral prednisolone at 10 mg once daily over the first
six months of ASIT showed an increased percentage of
eosinophils in the BALF after nine months of ASIT by con-
trast with inhaled fluticasone at 220 mcg twice daily.65
Adverse effects
Adverse effects were not mentioned in ten
reports.12,23,25,29–32,59,65,76 After RIT, two of four cats
showed increased pruritus and in two of four a dermal
alopecic nodule developed one week after initiation of
therapy.13
Recommendations
ASIT seems to be an efficacious therapy for FASS (QOE
2; SOR B). However, some studies were presented only
as abstracts with very limited information,23,25 none of
the studies were controlled or randomised, and all were
characterised by unclear outcome measures, making final
assessment difficult. By contrast, there is evidence of
moderate-to-good efficacy of ASIT in naturally occurring
feline asthma (QOE 2; SOR B) and moderate efficacy of
RIT in cats with experimental asthma (QOE 1; SOR A).
Adverse effects seem to be rare (QOE 1; SOR A). More
studies on ASIT in cats are needed urgently.
Systemic glucocorticoids
Analysis of evidence
Three prospective double-blinded RCTs evaluated sys-
temic glucocorticoid treatment in cats with FASS.60,62,64
One prospective study looked at the diabetogenic poten-
tial of prednisolone and dexamethasone in healthy cats.56
The three clinical trials included 63 cats: 11 treated with
prednisolone, 36 with methylprednisolone and 16 with tri-
amcinolone. The treatment regimens used dosages of
1 mg/kg once daily of prednisolone, 0.77 mg/kg twice
daily (20 cats) to 1.4 mg/kg once daily (16 cats) of methyl-
prednisolone, and 0.18 mg/kg once daily of triamcinolone
acetonide for 2862,64 to 8460 days. The latter study used
daily treatment for ≤14 days to achieve remission and
then tapered treatment resulting in final alternate day
dosages of 0.54 mg/kg methylprednisolone and 0.08 mg/
kg triamcinolone.60 Pruritus was assessed using a 0–10
Visual Analog Scale82 (pVAS) in two studies60,62 and a 0–
5 Linear Analog Scale in one.64 Lesion scores were
assessed using the Canine Atopic Dermatitis Extent and
Severity Index, 2nd iteration (CADESI-02),64,83 a Feline
Table 3. Responses to allergen immunotherapy in 82 cats with naturally occuring and experimental asthma
Type of Allergen (number of
cats evaluated) Dosage Responses
References
Type of study QOE
Alum-precipitated allergens
(n = 12, EX)
200 mcg weekly Bermuda
grass allergen SC or
intranasally for six months
Respiratory scores and
eosinophil % in BALF
decreased,




(n = 18, EX)
200 mcg weekly Bermuda
grass allergen SC for nine
months, additional oral or
inhaled glucocorticoids for
the first six months (n = 6
each)
Decrease in eosinophil% and IL-
5 in BALF




(n = 36, EX)
200 mcg/week for six months Decrease in eosinophil% and
lymphocyte proliferation
stimulation index, increase in
CD4 + CD25+ FoxP3 + T cells






1 mL every 28 days for six to
nine months
Remission in 8/12 cats Prost 200847
Case series
2
Not reported (n = 4) Not reported Mean percentage clinical
improvement 89.5%
Halliwell 199729 ReSt 3
BALF bronchoalveolar lavage fluid, EX experimental asthma, NO naturally occuring asthma, QOE quality of evidence, ReSt retrospective study,
RCT randomised controlled trial, SC subcutaneously.
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Erythema, Excoriation and Alopecia score (FEEAS; a mod-
ified CADESI-03 score omitting lichenification),60 and a
Scoring Feline Allergic Dermatitis (SCORFAD) scale.62
Only the SCORFAD scale had been validated for pruritic
and eosinophilic skin lesions in cats.84,85 One study62
included a validated Quality of Life (QoL) score.86 The
cats presented with pruritus and a variety of the recog-
nised reaction patterns associated with FASS. Most cats
presented with more than one type of lesion. The season-
ality of the clinical signs was not recorded.
One cross-over RCT compared oral prednisolone at
10 mg/day with inhaled flunisolide at 250 µg twice daily
in six cats with feline asthma experimentally sensitised to
Bermuda grass.66 Another cross-over RCT treated six
cats sensitised to A. suum with either oral prednisolone
at 1 mg/kg twice daily, 500 mcg of inhaled fluticasone
proprionate twice daily, or a combination of inhaled fluti-
casone propionate and salbutamol at 500 mcg and
50 mcg, respectively, for four consecutive days.71 A
study with 14 client-owned cats with lower airway dis-
ease assessed airway function before and after pred-
nisolone therapy.48
Analysis of efficacy
Treatment outcome data were available for 63 cases with
FASS (see Table 4). Cats that responded to treatment
were reported to do so within 7–14 days. There was no
association between the responses to treatment and the
type of lesions.
Although prednisolone decreased allergen-specific IgE
and the percentage of eosinophils in the BALF of cats
experimentally sensitised to Bermuda grass, it did not
improve airway hyper-reactivity in response to metha-
choline.66 In the A. suum-sensitised cats there were no
significant differences in respiratory rate or Penh [an esti-
mate of airflow limitation measured by conventional baro-
metric whole body plethysmography (BWBP)] between
the treatment groups.71 Allergen-induced airway hyper-
responsiveness was significantly inhibited by the oral
prednisolone, inhaled fluticasone proprionate and inhaled
fluticasone propionate/salbutamol. The mean BALF
eosinophil percentage was lower after oral and inhaled
corticosteroid treatment and these changes were signifi-
cant for groups receiving prednisolone and the combina-
tion of inhaled fluticasone propionate/salbutamol,71
although the dose of inhaled fluticasone was fairly high.
In the study with client-owned cats with lower airway dis-
ease, a significantly decreased peak to mid-expiratory
flow and no significant changes in other BWBP parame-
ters were noted after at least three weeks of therapy with
prednisolone at 1.2–2 mg/kg once daily.48
Adverse effects
Clinical adverse effects were uncommon, with one case
each of vomiting and lethargy among the 20 cats treated
with methylprednisolone.62 Clinicopathological abnormali-
ties included increased liver enzymes in one of 16 triamci-
nolone- and eight of 36 methylprednisolone-treated
cats.60,62 Hyperglycaemia was seen in four, altered
haematological parameters in four, and glycosuria in one
of the 36 methylprednisolone-treated cats. Mean albumin
and fructosamine levels significantly increased in triamci-
nolone- (n = 16) and methylprednisolone-treated cats
(n = 16) and remained within the reference ranges.60
Amylase was elevated above the reference range in 10 of
15 triamcinolone- and two of 14 methylprednisolone-trea-
ted cats at the end of the induction phase, and returned
to normal during the every other day maintenance
phase.60 The safety study evaluated 14 cats treated with
either 4.4 mg/kg once daily of prednisolone or 0.55 mg/
kg once daily of dexamethasone for 56 days.56 Dexam-
ethasone treatment resulted in significantly increased
fructosamine concentration, decreased insulin sensitivity
and secretion, and increased glycosuria, although the cats
did not become hyperglycaemic at any point. No adverse
effects were mentioned in most of the studies evaluating
asthmatic cats.48,66,71 One study evaluated long-term
effects of glucocorticoids in asthmatic cats and found
adverse effects such as polyuria and polydipsia, diabetes
mellitus and fungal infection in four of 34 cats.27 A study
evaluating long-term safety (at least three years) of
methylprednisolone in 25 cats detected an increase of
Table 4. Responses to systemic glucocorticoid treatment in 63 cats with feline atopic skin syndrome (FASS)
Glucocorticoid‡ (number
of cats evaluated) Dosage
Response to treatment†
References
Type of study QOEPruritus Lesion scores QoL
Methylprednisolone
(n = 16, not all cats had
an elimination diet)
1.4 mg/kg once
daily for over six weeks






daily for 28 days




(n = 16, not all cats had
an elimination diet)
0.18 mg/kg once
daily for over six weeks
95% decrease¶ 70% decrease¶ ND Ganz 201260
RCT
1
Prednisolone (n = 11) 1 mg/kg once
daily for 28 days
5/11 improved
6/11 worse
6.9% 77.8%‡ ND Wisselink 200964
RCT
2
ND not determined, QoL quality of life (lower scores are better), ReSt retrospective study, RCT randomised controlled trial.
†
See text for the definitions of the responses to treatment.
‡
Mean improvement  standard deviation.
§
13 of 16 cats achieved remission.
¶
Two of three cats that failed to achieve remission responded to higher doses of glucocorticoid.
††
Three of 20 cats worsened.
‡‡
14 of 16 cats achieved remission.
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triglycerides, amylase and monocytes, yet changes
remained within the reference interval.87
Recommendations
Systemic glucocorticoids are rapid and effective in most
cats with FASS (QOE 1; SOR A). Treatment with 1.4–
1.5 mg/kg once daily of methylprednisolone-induced
remission in 33 of 36 cats within 14 days. The similar
response to 0.18 mg/kg once daily of triamcinolone ace-
tonide suggests that this drug has seven-fold greater
potency than methylprednisolone. It is therefore likely
that equipotent doses of other glucocorticoids will be like-
wise effective (QOE 3; SOR C). By contrast, 1 mg/kg
once daily of prednisolone (approximately 50% of the
above dosages) was much less effective. Once in remis-
sion, treatment can be tapered to the lowest and least
frequent dosage that maintains remission (QOE 1; SOR
A). On average, this equated to 20–25% of the starting
dosage. Once-daily treatment is advised (QOE 1; SOR A).
There was no difference in the efficacy of methylpred-
nisolone at 0.77 mg/kg twice daily and 1.4 mg/kg once
daily. One study noted that twice-daily dosing reduced
QoL scores.62 Systemic glucocorticoids at these doses
were well-tolerated, although all of the studies were
short-term. However, altered haematology, serum bio-
chemistry and urinalysis parameters were frequent (par-
ticularly markers of glucose metabolism). Regular
monitoring of cats on a long-term treatment with sys-
temic glucocorticoids is therefore warranted, especially
with more diabetogenic drugs such as dexamethasone
(QOE 1, SOR A).
In feline asthma, there is good evidence for clinical effi-
cacy of oral glucocorticoids (QOE 1; SOR A) although
most of this evidence is based on experimentally sensi-
tised cats.
Topical and inhaled glucocorticoids
Analysis of evidence
There was one prospective open and uncontrolled clinical
trial of topical 0.0584% hydrocortisone aceponate (HCA,
Cortavance, Virbac; Carros, France) in 10 cats with peren-
nial pruritus and lesions consistent with FASS.43 The cats
were treated with two sprays per 10 x 10 cm area of
affected skin from 10 cm away daily for 28 days, fol-
lowed by every other day dosing up to Day (D).43 The out-
come measures included a pVAS,82 a validated Feline
Dermatitis Extent and Severity Index lesion score
(FeDESI),84 and a five point categorical score for efficacy,
tolerance and ease-of-administration.
Four studies evaluated the use of inhaled glucocorti-
coids in an experimental model of feline asthma.65,66,68,71
In one study, inhaled flunisolide at 250 µg twice daily was
compared with oral prednisolone at 10 mg once daily in
six cats.66 In the second blinded cross-over RCT the
effect of three different dosages of inhaled fluticasone
propionate delivered by a metered-dose inhaler was
investigated in six cats with experimentally induced aller-
gic airway inflammation.68 A third cross-over RCT treated
six cats sensitised to A. suum with either prednisolone
(1 mg/kg twice daily), inhaled fluticasone propionate
(500 mcg twice daily), or a combination of inhaled
fluticasone propionate and salbutamol (500 mcg/50 mcg
twice daily) for four consecutive days.71 In another study,
sensitised cats underwent RIT and for the first six months
concurrently received either oral prednisolone at 10 mg/
kg/day/cat or 220 mcg twice-daily inhaled fluticasone/
cat.65 One study investigated the effects of 400 mcg of
inhaled budesonide twice daily on 37 cats with naturally
occurring asthma and chronic bronchitis in a retrospective
study using client questionnaires.34
Analysis of efficacy
Three cats were withdrawn from the HCA study; two
were lost to follow-up and one was removed owing to
poor efficacy.43 Using an intention-to-treat analysis, there
was a 77% reduction in FeDESI score and 76% reduction
in pruritus by D56. Over 50% of the improvement was
seen by D14. Ease-of-administration, tolerance and effi-
cacy assessments were good-to-excellent in the seven
cats that completed the study. Of these cats, six of seven
could be maintained on every other day treatment and
one required daily therapy.
Although inhaled flunisolide decreased allergen-specific
IgE and the number of eosinophils in the BALF of cats
experimentally sensitised to Bermuda grass
(Table 5),66,68 it did not improve airway hyper-reactivity to
methacholine.66 Fluticasone dosages of 44, 110 or
220 mcg twice daily for three weeks did not suppress the
hypothalamic–pituitary–adrenal axis.68 In the same experi-
mental model, inhaled fluticasone did not influence the
outcome of RIT in contrast to oral glucocorticoids (where
airway eosinophilia was significantly increased after nine
months of RIT), although the dose of prednisolone was
very high.65 In the study with the six cats sensitised to
A. suum, inhaled fluticasone propionate, or a fluticasone
propionate and salbutamol combination, resulted in signif-
icantly decreased allergen-induced airway hyper-respon-
siveness. The mean BALF eosinophil percentage was
significantly lower after the inhaled combination of flutica-
sone and salbutamol.71 In the study of naturally occurring
asthma or chronic bronchitis treated with budesonide,
close to a third of the cats were asymptomatic with ther-
apy, almost as many improved (Table 5).34 BWBP param-
eters had improved in the 19 cats where pre- and post-
examinations were available.34
Adverse effects
In the study using HCA in cats with FASS, no adverse
events were noted and there were no haematological,
biochemical or urine abnormalities in samples from four
of the cats.43 Four cats would not tolerate the spray
and the solution was applied directly using cotton wool.
There was no association between the response to
treatment and lesion type. In studies evaluating feline
asthma, clinical adverse effects to inhaled glucocorti-
coids were either not seen34,65 or not men-
tioned.66,68,71 Inhaled budesonide therapy was
associated with hypothalamic–pituitary–adrenal axis
suppression in one study.34
Recommendations
Topical 0.0584% HCA was rapidly effective in seven of
10 cats (QOE2; SOR B). It is likely that other topical
© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary
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glucocorticoids also will be effective depending on the
type and formulation of glucocorticoid (QOE 3; SOR C)
and topical treatment should be considered for FASS
whenever feasible (QOE 3; SOR C). This is likely to have
fewer adverse effects than systemic glucocorticoid treat-
ment. However, these products are not licenced for cats,
systemic absorption is possible and regular clinical moni-
toring is advised. There is good evidence that inhaled glu-
cocorticoids are beneficial for cats with asthma (QOE 1;
SOR A). No clinical adverse effects were reported,
although again monitoring of cats on long-term treatment
is advised. Hypothalamic–pituitary–adrenal axis suppres-




Ciclosporin use in FASS was evaluated in two double-
blinded, placebo-controlled studies,42,77 one double-
blinded, prednisolone-controlled study,64 three prospec-
tive open studies,40,46,88 one safety and tolerability
study,18 and three retrospective case series.22,31,33 In
two studies, specific clinical presentations were not men-
tioned,22,64 while the other studies31,33,40,46,77 included
cats with excoriations as a consequence of pruritus
(n = 185), self-induced alopecia (n = 181), eosinophilic
granuloma (n = 112) and miliary dermatitis (n = 100).
Most cats presented with more than one lesion type.
There is one case report of a cat with asthma, congestive
heart failure and diabetes mellitus treated successfully
with ciclosporin.14 Two other studies evaluated the effect
of ciclosporin on mast cell degranulation and airway
remodelling in a colony of cats sensitised to A. suum.74,89
In older studies, a human product of ciclosporin was used
(Neoral, Novartis; Basel, Switzerland),33,40,64 whereas in
newer studies, the veterinary product was administered
(Atopica, Novartis) and in one study both products were
used.31
Analysis of efficacy
Two double-blinded, placebo-controlled studies,42,77 one
double-blinded, prednisolone-controlled study,64 three
prospective open studies,40,46,88 and two retrospective
case series,31,33 reported the treatment outcome in 328
cases of FASS. In general, ciclosporin was effective in
40–100% of the cats. However, scoring systems for the
lesions varied. Many studies used a validated score such
as the SCORFAD,42,46,88 and others used the Feline Eosi-
nophilic Granuloma, Eosinophilic Plaque, Extension and
Severity Index (FEGEPESI),40 or a score devised as a total
lesion score (TLS) describing the extent and severity on a
scale from 0 to 4 for each of the major reaction patterns
seen in FASS.77 One study64 used a CADESI-02 score val-
idated for cAD.90,91 Owner-assessed pruritus was evalu-
ated in most studies using a pVAS,40,46,77,88 yet one
study used a scale from 1 to 5,64 and another used a scale
from 1 to 10.33 The latter study also evaluated the lesions
on a 1–10 scale .33 Only two studies used owner global
assessments.42,77 Finally, one retrospective study did not
consider pruritus or lesions, and rather evaluated the
owners’ impressions of various treatments.31 One
study88 was a follow-up of a double-blinded, placebo-con-
trolled study and evaluated tapering schedules for ciclos-
porin in cats.42 During the final four weeks of that
particular study, 63%, 22% and 15% of 157 cats could be
maintained on twice-weekly, every other day or daily
treatment, respectively.42 Likewise, in another open
study ciclosporin could be tapered to every other day in
15% and twice weekly in 57% of the cats.46 Results of
the various studies are listed in Table 6.
Ciclosporin did not affect mast cell degranulation or the
early asthmatic response in A. suum-sensitised cats with
induced asthma.74 However, in another study by the
same group, ciclosporin was shown to reduce airway
reactivity and remodelling after chronic antigen challenge
in cats sensitised to A. suum.89 Ciclosporin also was
used in a cat with feline asthma and concurrent conges-
tive heart failure and diabetes mellitus at a dosage of
4 mg/kg twice daily.14 Clinical signs and airway eosinophi-
lia resolved completely within three weeks of therapy.
However, thereafter the ciclosporin was replaced with
inhaled fluticasone and long-term effects of the ciclos-
porin could not be evaluated.14
Adverse effects
In all studies, gastrointestinal signs were the most com-
mon adverse effects. In one study, vomiting, diarrhoea
Table 5. Responses to inhaled glucocorticoids in 67 cats with asthma
Inhaled glucocorticoid





400 mcg twice daily for less than
two months
Clinical improvement in 23/43,







220 mcg twice daily for six months
concurrent to ASIT












Fluticasone (n = 6) 44 mcg twice daily, 110 mcg twice
daily and 220 mcg twice daily in a
cross-over design
Reduction of airway eosinophilia Cohn 201068 RCT 1
Flunisolide (n = 6) 250 mcg twice daily for two weeks Decrease in BALF eosinophils Reinero 200566
RCT
1
ASIT allergen (-specific) immunotherapy, BALF bronchoalveolar lavage fluid, Penh enhanced pause, QOE quality of evidence, RCT randomised con-
trolled trial, ReSt retrospective study.
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and/or anorexia was noted in 12 of 50 and weight loss
in eight of 50 cats.22 Gingival hyperplasia, a known
adverse effect in dogs, occurred once.22 In one study,
vomiting occurred in 26 of 65 and diarrhoea in 13 of 65
cats.46 In another study, diarrhoea was more common
(in five of 18) than intermittent vomiting (three of 18).64
In one study,77 the neutrophil and eosinophil cell count
decreased significantly in the high-dose group, and still
was within the reference range. An elevation in total
bilirubin, urea and glucose also was seen in the high-
dose group, yet again all values were within the refer-
ence range. Nonsignificant weight loss was seen in the
first three weeks, and reversed in the second three
weeks of the study when the medication, initially
mixed with food, was given separately orally.77 Crypto-
coccosis and toxoplasmosis developed in one and two
of ten cats, respectively, in one retrospective study.31
In a larger study, 10 of 144 cats receiving ciclosporin
had a positive Toxoplasma titre.42 Other adverse
effects included anorexia, lethargy, sneezing and
weight loss, at least one of which occurred on daily
ciclosporin in 80% of cases in one report.46 Increased
appetite and polydipsia (in one cat each) were seen in
another study.64 In one study none of the 32 cats on
glucocorticoids or ciclosporin for at least six months
showed subclinical bacteriuria, when urine obtained by
cystocentesis was evaluated.92 Although not reported
in any of the cited studies, acute bullous keratopathy
was significantly associated with systemic administra-
tion of ciclosporin in cats in a larger study evaluating
12 patients that had developed this disease in a popula-
tion of 70,167 cats.93
Recommendations
Based on the available evidence in a large number of cats
with FASS, ciclosporin at a dose of 7 mg/kg once daily is
efficacious in the treatment of reaction patterns caused
by FASS (QOE 1; SOR A). In more than half of the cats,
ciclosporin could be tapered from daily to twice-weekly
administration.46,88 By contrast, there is insufficient evi-
dence to recommend ciclosporin for feline asthma. As
reported in dogs,94 gastrointestinal adverse effects are
the most common. There is evidence that cats that get
infected with Toxoplasma gondii while receiving ciclos-
porin daily develop much more severe clinical signs,17 or
even die.9,11,17 By contrast, shedding of oocysts or recur-
rence of clinical signs was not seen in cats already
infected with Toxoplasma before ciclosporin administra-
tion.17 Consequently, Toxoplasma antibody titres may be
recommended before ciclosporin therapy and may














daily for 42 days
Mean (SD) 7.3 (3.0) to 2.5
(2.8)
Mean (SD) 69













in three cats: 2–
4 mg/kg once
daily











Mean (SD) 7.3 (3.5)
decreased to 2.3 (2.7) in
first 28 days
Mean (SD) 66 (23)
decreased to 26 (29)










Mean (SD) 6.8 (2.8)
decreased to 1.8 (1.5); 15
improvement > 50%
Mean (SD) 69 (23)















Mean (SD) 7.7 (3.9)
decreased to 2.9 (2.7); 23
improvement > 50%
Mean (SD) 66 (21)











5 mg/kg daily for
28 days
Improvement by 38% (SD
45%), 13/18
improvement by > 25%
Pruritus improved in
61%








daily for 30 days
FEGEPESI decreased from
7.5 to 3.6, 5
improvement > 50%
Decreased from 8.5 to
4.6, 4
improvement > 50%









All cats but 1 cured (1
euthanasia)
All cats but 1 in clinical
remission (1
euthanasia)




FEGEPESI Feline Eosinophilic Granuloma, Eosinophilic Plaque, Extension and Severity Index, QOE quality of evidence, RCT randomised controlled
trial, ReSt retrospective study.
†
See text for details of the outcome measures.
‡
0 = excellent, 1 = good, 2 = acceptable, 3 = poor, 4 = bad.
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influence the treatment decision in seronegative cats
with access to outdoors or fed raw meat (QOE2; SOR B).
Oclacitinib
Analysis of evidence
One case report,10 two open prospective studies24,41 and
one methylprednisolone-controlled double-blinded
study62 reported the efficacy of oclacitinib for FASS.
These included 68 cats, 48 of whom were treated with
oclacitinib. In one abstract, details of the improvements
were not given.24 The outcome measures of the other
two prospective studies were a clinician-assessed
lesional score, the SCORFAD and an owner-based
pVAS.41,62 One study did not specify the lesion type,62
and the other studies included 19 cats with excoriations
on the head and neck, eight cats with self-induced alope-
cia, four cats with eosinophilic granuloma and one cat
with miliary dermatitis.10,24,41 Most cats presented with
more than one lesion type. Seasonality was not recorded
for any cat. In a randomised, placebo-controlled study, 24
cats with induced asthma experimentally sensitised to
Bermuda grass received oclacitinib at 0.5 or 1.0 mg/kg
twice daily for four weeks and airway inflammation was
monitored.26 In addition, a more recent study docu-
mented a more rapid elimination of oclacitinib in the cat
versus the dog, and recommended a shorter dose interval
and/or higher doses of oclacitinib in cats compared to
dogs.19
Analysis of efficacy
Treatment outcome data were available for all 48 cats
with FASS (see Table 7). Cats that responded to treat-
ment were reported to do so within one month. Overall, a
good response was reported at a dosage of 1 mg/kg once
or twice daily. One third of the cats had a good-to-excel-
lent response in one study.41 In one case report with
long-term follow-up, the cat achieved long-term clinical
remission while on therapy.10
In the study evaluating the two doses of oclacitinib (0.5
or 1.0 mg/kg twice daily) in cats with experimental
asthma, the percentage of eosinophils in BALF was sig-
nificantly decreased compared to placebo with no differ-
ence between the two dosages.26 There was no
significant difference between treatment groups in the
effective concentration of methacholine that induced a
200% increase over baseline airway resistance.26
Adverse effects
Adverse effects were not specifically recorded in two
studies,24,41 although in one study owners reported the
drug to be clinically well-tolerated by all cats.41 In another
study, at least half of the cats were monitored with com-
plete blood counts and serum biochemistry with neu-
tropenia seen in two, thrombocytopenia in one, increased
blood ureanitrogen and creatinine in four, and increased
alanine aminotransferase in three cats.62 In the case
report monthly serum biochemistries and complete blood
counts for 10 months did not show any changes.10 In a
recent placebo-controlled safety study, oclacitinib was
administered at 1 and 2 mg/kg twice daily for 28 days.95
Vomiting and soft stools were noted in two of 10 cats
each in the high-dose group. A small increase in fruc-
tosamine concentrations was observed for both treated
groups compared with placebo; however, values
remained within the normal reference range. There were
no differences in individual parameters in complete blood
counts and biochemistry panels. In the study of cats with
experimental asthma, no adverse effects were noted in
the four weeks of treatment.26
Recommendations
Oclacitinib at a dosage of approximately 1 mg/kg once or
twice daily was an efficacious treatment option for FASS
(QOE1; SOR A). Based on the small number of cats and
the short duration of most studies as well as the lack of
long-term safety data and the off-label use of the drug,
cats receiving oclacitinib should be monitored closely until
Table 7. Responses to oclacitinib treatment in 48 cats with feline atopic skin syndrome (FASS)
Dose (number of cats
evaluated)
Global efficacy by owner
SCORFAD;
MEAN (SD) pVAS; mean (SD)
References




0.7–1.2 mg/kg twice daily for
28 days (n = 20)
11 4 5 6.2 (2.3) and 2.4 (2)
before and after; >50%
in 12
7.5 (1.5) and 3.4 (3)
before and after;
>50% in 15/20;
>2 cm in 11
Noli et al. 201962
RCT
1
1 mg/kg twice daily for
14 days, then once daily for
300 days, then twice daily
(n = 1)
N/A N/A N/A Remission after 30 days, relapse after 300 days
on once daily, and then remission again on twice
daily
Fernandes et al. 201910
Case reports
2
0.5–0.8 mg/kg twice daily for
14 days, then once daily for
14 days (n = 15)
N/A N/A N/A 10 improved† 10 improved† Pandolfi et al. 201624
Case series
2
0.4–0.6 mg/kg twice daily for
14 days, then once daily for
14 days (n = 12)
4 3 5 4.9 (2.4) and 3.6 (3)
before and after
8.5 (1.6) and 7 (2.5)
before and after




pVAS pruritus Visual Analog Scale, QOE quality of evidence, RCT randomised controlled trial, ReSt Retrospective study, SCORFAD Scoring Feline
Allergic Dermatitis.
†
No further details were given in the abstract.
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more data are available. There also is only limited evi-
dence for the use of oclacitinib in asthmatic cats (QOE2;
SOR B) and, to the best of the authors’ knowledge, no




One study evaluated salbutamol, ipratropium bromide
and the combination of those two drugs in cats sensitised
to ovalbumin and to A. suum compared to control cats.69
In another study, the same drugs were used in a double-
blinded, placebo-controlled cross-over design in A. suum-
sensitised cats.70 In a clinical study including 19 cats with
naturally occuring bronchial disease, therapy with low-
dose prednisolone was supplemented with propento-
fylline in 10 cats.57
Analysis of efficacy
In the first study, cats sensitised to ovalbumin (n = 6), to
A. suum (n = 6) and nonsensitised control cats (n = 6)
were evaluated.69 Salbutamol (100 mcg, two puffs), iprat-
ropium bromide (20 mcg, two puffs) or a combination of
salbutamol and ipratropium bromide (120 mcg/20 mcg,
two puffs) were administrated to the conscious cats by
use of a pressurized metered-dose inhaler and a spacing
chamber connected through an inspiratory valve to a face-
mask. Salbutamol/ipratropium bromide reduced BAL-in-
duced bronchoconstriction in the cats sensitised to
A. suum, and not in the cats sensitised to ovalbumin or
control cats. By contrast, salbutamol or ipratropium bro-
mide alone did not lead to any significant changes.69 In
the cross-over study with five cats sensitised to A. suum,
enhanced pause, an estimator of airflow limitation mea-
sured by BWBP, was repeatedly assessed within
120 min following the administration of each treatment
protocol.70 Responses to inhaled medications were evalu-
ated by calculating the area under the time–response
curves (AUC) from 0 to 60 or 120 min after drug adminis-
tration (AUC0–60, AUC0–120), as well as the times required
for half-recovery or for returning to nearly basal condi-
tions. There was no difference in time-related bronchodi-
lating effects between 100 mcg salbutamol, 20 mcg
ipratropium bromide, a combination of the two treat-
ments, and the nontreated control.70 Cats treated with a
combination of propentophylline and prednisolone signifi-
cantly improved in their auscultation scores, respiratory
pattern scores and radiological bronchial markings score
over the observation period, and they coughed less and
were more active at the end of the study compared to the
cats treated with prednisolone alone.57
Adverse effects
No adverse reactions occurred in one study,69 adverse
effects were not mentioned in two.57,70
Recommendations
Although bronchodilators are frequently recommended
for the treatment of feline asthma,96,97 the two evaluated
studies provided no evidence supporting the use of bron-
chodilators in asthmatic cats (QOE2; SOR B). Moreover,
both trials were with cats experimentally sensitised in the
laboratory and studies evaluating bronchodilators in cats
with naturally occurring asthma are lacking. Despite this,
inhaled bronchodilators are recommended for manage-
ment of acute asthmatic episodes and for long-term treat-
ment of feline asthma alongside inhaled steroids (QOE3;




There were seven open and uncontrolled studies report-
ing the efficacy of H1R-antihistamines in FASS; six were
prospective36–38,44,45,51 and one was retrospective.31
One study was prospective, double-blinded and placebo-
controlled.63 These included 164 cats: 37 treated with
chlorphenamine/chlorpheniramine maleate (11 received
concurrent omega three of six essential fatty acids),37,44
10 with clemastine fumarate,38 20 with cyproheptadine
hydrochloride,45 51 with cetirizine36,63 and 46 with lorati-
dine.31,51 The outcome measures varied with the five
prospective studies using owner-assessed pVAS (reduc-
tions of 0–25% poor, 26–50% fair, 51–75% good and 76–
100% excellent in four studies; and ≤25% mild, 25–50%
moderate and ≥50%marked in one study). The retrospec-
tive study defined a “good” response as a marked reduc-
tion or resolution of clinical lesions and reduction or
discontinuation of ongoing symptomatic medications, a
“partial” as a reduction in clinical lesions with ongoing
antipruritic drugs, and “no response” with no apparent
change to lesions, pruritus and/or symptomatic medica-
tions. The cats presented with pruritus and a variety of
the recognised reaction patterns associated with FASS.
Most cats presented with more than one type of lesion.
Seasonality was recorded for 99 cats, with 90 having
perennial disease and nine seasonal disease. Two studies
evaluated cetirizine and cyproheptadine in a model of
feline asthma.66,67 Unfortunately, only two studies
reported pharmacokinetic data of antihistamines in
cats.20,21 Oral cyproheptadine was well-absorbed and
had a half life of approximately 12 h.20 Cetirizine was
well-absorbed after oral administration, with higher
plasma concentrations than seen in humans and a half-life
compatible with once-daily dosing.21
Analysis of efficacy
Treatment outcome data were available for 164 cats with
FASS (see Table 8). Cats that responded to treatment
were reported to do so within three to 10 days of starting
treatment and to relapse within two to three days of stop-
ping. There was no association between the responses
to treatment and the type of lesions or seasonality.
A retrospective study31 (QOE 3) reviewed type 1 anti-
histamine treatment in 31 cats. However, with the excep-
tion of cetirizine (n = 19) and loratidine (n = 18)
(outcomes included in Table 6), specific treatments and
outcomes were not reported. Most cats received more
than one antihistamine with variable and inconsistent
results. Overall, a good response was reported in two of
31, a partial response in 20 of 31, and a poor response in
nine of 31 cats.31
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When used in a model of feline asthma, antihistami-
nes such as cetirizine and cyproheptadine did not
alter percentage of eosinophils in BALF, or sero-
tonin and histamine concentrations in plasma or
BALF.66,67
Adverse effects
Most of the antihistamines were reported to be well-
tolerated. Adverse effects included sedation in two of
37 cats treated with chlorphenamine and diarrhoea in
one of 10 cats given clemastine. However, adverse
effects were reported in 11 of 20 cats treated with
cyproheptadine; three cats were withdrawn from treat-
ment (one with vomiting, two with polyphagia) and
adverse effects were reported in another eight cats
(vomiting in one, polyphagia in four and altered beha-
viour/vocalisation in four).
Recommendations
Oral antihistamines could provide a small and limited
benefit in some cats with FASS and this is not likely
to result in good-to-excellent response in most cases
(QOE 2; SOR B). The available evidence supports the
use of chlorphenamine as a first-line H1R-antihis-
tamine (QOE 2; SOR B). The mode of action of these
drugs in cats is unknown yet, based on recommenda-
tions in cAD,8 it is likely that they will be most effec-
tive in early and/or mild disease and when given
proactively rather than reactively to manage an acute
exacerbation (QOE3; SOR C). It is also possible that
the sedative effect of first generation H1R-antihistami-
nes may alleviate stress-associated triggers in FASS
(QOE3; SOR C). The high frequency of adverse
effects to cyproheptadine is of concern (QOE2; SOR
B). There is no evidence supporting the use of antihis-
tamines in cats with asthma (QOE2; SOR B).
Essential fatty acids and palmitoylethanolamide
Analysis of evidence
Treatment outcome data were available for 37 cats with
FASS (see Table 9). In one prospective, double-blinded,
placebo-controlled study 15 cats either received evening
primrose oil (EPO) or olive oil as the placebo for 12
weeks.61 There was one prospective, double-blinded, pla-
cebo-controlled study evaluating 15 cats with FASS,61
two randomised studies with 1154 and 1453 atopic cats,
one prospective study with 10 cats with FASS (and 18
cats with food allergy, flea bite hypersensitivity or miliary
dermatitis, self-induced alopecia or eosinophilic granu-
loma without further diagnostic work-up)39 and 12 cats
with miliary dermatitis,55 respectively. In another study,
healthy cats were given essential fatty acids as a supple-
ment to a standard diet.98 In some studies, cytological
evaluation, fungal cultures, skin scrapings, flea control and
elimination diets were performed as needed before inclu-
sion to confirm the diagnosis of FASS.53,54,61 In others,
cats showed clinical features of FASS, and differential
diagnoses were not55 or not always39 evaluated. In three
studies, only cats with miliary dermatitis (n = 30) were
included.53–55 In an open label study, 15 cats with nonflea-
associated FASS were given 10 mg/kg ultramicronised
palmitoylethanolamide (PEAum) twice daily for 30 days.
The outcome measures were a clinical assessment (pruri-
tus, erythema, alopecia, and extent of eosinophilic pla-
ques and granulomas) and evaluation of mast cell
numbers in skin biopsies.50 One double-blinded, placebo-
controlled randomised trial assessed the efficacy of
PEAum in maintaining remission in cats with nonseasonal
pruritus and FASS (described as nonflea-associated hyper-
sensitivity dermatitis with a variety of reaction patterns).99
The cats initially were stabilised with two weeks of
methylprednisolone (4–6 mg/cat/day) and then main-
tained on PEAum (n = 21; approximately 15 mg/kg/day)














5 mg/cat once daily for 14 days 4% 17%e 79% Ravens et al 201431
ReSt Scott et al 201551
Case series
3 2
Cetirizine (n = 19) 1 mg/kg once daily for 28 days 0% 11% 89% Wildermuth et al 201363
RCT
1





2 mg/cat twice daily for 14 days 45% 0 55% Scott et al 199845 Case series 2
Chlorpheniramine
(n = 37)
2 mg/cat twice daily for 14 days 70% 0 30%‡ Miller and Scott 199037





0.34 mg/cat twice daily for two
weeks, then 0.68 mg/cat twice
daily for two weeks
50% 0 50% Miller and Scott 199438
Case series
2
Mean outcomes 36% 6% 58%
QOE quality of evidence, RCT randomised controlled trial, ReSt Retrospective study.
†
See text for the definitions of the responses to treatment.
‡
Five of 11 nonresponders were concurrently treated with an omega3/omega6 essential fatty acid supplement.
§
Median pruritus scores decreased from 5.25 to 5 (all cats) or 2.75 (responders).
¶
Includes five cats with a mild improvement; eall in one retrospective study.31
© 2021 The Authors. Veterinary Dermatology published by John Wiley & Sons Ltd on behalf of the European Society of Veterinary
Dermatology and the American College of Veterinary Dermatology., 32, 43–e8. 53
Feline atopic syndrome: treatment
or placebo (n = 23) alone. The outcome was the time to
relapse [≥2 point increase and/or score ≥ 4 in SCORFAD,
≥2 cm increase in pVAS or global assessment score of 3
(0–3 scale)]. One study assessed the preventive effects
of omega-3 polyunsaturated fatty acids (omega3 PUFA)
and luteolin supplementation on allergen-induced airway
inflammation in eight A. suum-sensitised cats.49
Analysis of efficacy
In one prospective, double-blinded, placebo-controlled
study, 15 cats either received evening primrose oil (EPO)
or olive oil as the placebo for 12 weeks.61 Mean pruritus,
erythema, alopecia and overall scores did not improve sig-
nificantly, nor was there a significant difference between
groups. Two owners in each group considered their cats
partially improved.61 In another randomised study, 11
cats received either EPO (n = 6) or sunflower oil (n = 5)
for 12 weeks. Mean overall clinical, self-trauma and
crusted papule scores decreased by >50% in both
groups.54 In another study evaluating 14 cats with miliary
dermatitis, seven of 14 showed good improvement after
six weeks of 0.5 mL EPO/cat once daily.53 When com-
bined with fish oil for another six weeks, 11 of 14 cats
showed a good response (the “good response” was not
further defined). When given fish oil for another six
weeks without the EPO, clinical signs recurred in 10 of 11
cats.53 Five healthy cats and five cats with miliary der-
matitis were administered an oil preparation with 33%
omega 3 and omega 6 fatty acids in a ratio of 1:2, while
five healthy cats and seven cats with miliary dermatitis
were not treated.55 Serum concentrations of eicosapen-
taenoic acid (EPA, 20:5n-3) and docosahexaenoic acid
(DHA, 22:6n-3) increased in the treated cats and the mil-
iary dermatitis resolved in three of five affected cats.55 In
a further study, healthy cats were given a fish oil (FO;
EPA and DHA) or a flax seed oil [FSO; a-linolenic acid
(ALNA, 18:3n-3)] supplement (n = 14 in each group) to a
standard diet (n-6:n-3 ratio 20:1) to achieve an n-6:n-3
ratio of 5:1.98 The supplements and diets were given for
12 weeks. Cutaneous reactions to histamine were
reduced by 20–40% after FO and by 50% after FSO. FO
raised leukotriene B (LTB) 5 levels and decreased the
LTB4:LTB5 ratio; and FO and FSO decreased B, T-helper
and total T-cell numbers, as well as proliferation to poke-
weed mitogen. However, there was no effect on T-cyto-
toxic, natural killer and MHC class II cells, delayed type
(type 4 cell-mediated) hypersensitivity, IL-2 expression or
plasma IgG concentration, or concanavalin A or phyto-
haemagglutinin-triggered stimulation. No adverse effects
were reported in any of these studies. In the uncontrolled
trial of PEAum,50 pruritus/erythema/alopecia improved in
64.3% of the cats and eosinophilic dermatitis lesions in
66.7% (three of 15 completely resolved). There was no
change in mast cell numbers, although their granularity
increased. No adverse effects were noted. In the RCT
assessing maintenance of methylprednisolone-induced
remission of FASS,99 the mean time to relapse was sig-
nificantly longer in the PEAum group (40.5 days; 13 of 19
cats relapsed) than the placebo group (22.2 days; 12 of
22 cats relapsed). Pruritus scores were significantly lower
in the PEA-treated cats and there was no difference in
lesion scores. Gastrointestinal effects were seen in four
PEAum-treated cats (two withdrawn) and six placebo-
treated cats (one withdrawn).
When eight asthmatic cats sensitised to A. suum
received four weeks of omega-3 fatty acids (20 mg once
daily) and luteolin (10 mg once daily), analysis of BALF
total and differential cell counts did not reveal any signifi-
cant differences between treated and untreated
A. suum-stimulated cats.49 However, concentrations of
leukotriene A4 increased and airway responsiveness
decreased after the supplement intake.49
Recommendations
Based on available data, there is limited evidence for
moderate efficacy of EFA supplementation in cats with
miliary dermatitis (QOE2; SOR B). A single study in
healthy cats showed decreased reactivity to histamine
with variable and moderate suppression of B- and T-cell
function.98 However, the clinical relevance of these find-
ings remains unknown. There is moderate evidence of
moderate efficacy for PEAum in FASS (QOE2; SOR B).
There is insufficient evidence for the benefit of EFAs or
PEAum in feline asthma.
Maropitant
Analysis of evidence
One open study evaluated maropitant at 2 mg/kg orally
once daily for four weeks as treatment for cats with
FASS.52 Two randomised, placebo-controlled studies
looked at the effect of maropitant on acute and chronic
asthma, respectively, in experimentally sensitised
cats.78,79
Analysis of efficacy
Maropitant decreased SCORFAD from 7.8 to 2.2 and pru-
ritus scores from 7.1 to 2.3, respectively, in 12 cats with
FASS.52 Ten of those cats improved by >50% in lesions,
and 11 of 12 by >50% in pruritus.
When administered to artificially sensitised cats with
feline asthma at 2 mg/kg subcutaneously immediately
after allergen challenge, maropitant did not diminish clini-
cal scores or airway eosinophilia.79 Likewise, there was
no difference in clinical scores or airway eosinophilia
when sensitised cats were administered maropitant at
2 mg/kg every 48 h for four weeks, although daily admin-
istration was not evaluated.78
Adverse effects
Increased salivation immediately after maropitant admin-
istration occured in two of 12 cats with FASS.52
Recommendations
There is limited evidence of good efficacy for maropitant
in FASS (QOE2; SOR B). There is currently no evidence




There was one double-blinded, placebo-controlled study
on the efficacy of oral amoxicillin-clavulanate
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[Clavamox; Pfizer Animal Health (now Zoetis): Madison,
NJ, USA] on eosinophilic plaques (amoxicillin-clavu-
lanate 12–14.6 mg/kg twice daily, n = 4; placebo,
n = 5) and indolent ulcers (amoxicillin-clavulanate 12–
16.2 mg/kg twice daily, n = 4; placebo, n = 4).75 All of
the cats had cytological evidence of infection with neu-
trophils and intracellular bacteria at entry. The cats
were treated for three weeks with no other treatment
apart from flea control. No adverse reactions were
reported. Another study evaluated the influence of
doxycycline (5 mg/kg twice daily) on cats with experi-
mentally induced asthma.58
Analysis of efficacy
Treatment with amoxicillin-clavulanate significantly
reduced the mean lesion size of the eosinophilic pla-
ques by 96% and indolent ulcers by 43% compared
to the placebo (0% and 37% increases, respectively).
There also was a decrease in the number of high-
power microscope fields with cytological evidence of
infection of 80% in the eosinophilic plaque group and
65% in the indolent ulcer group compared to placebo
(16% decrease and 13% increase, respectively).75 It
needs to be pointed out that eosinophilic plaques,
indolent ulcers and linear granulomas are reaction pat-
terns associated with other underlying allergic and
nonallergic causes, and those cats were diagnosed
with secondary bacterial infections. In cats with
asthma, four days of doxycycline did not influence the
early or late asthmatic response.58
Recommendations
The small and well-conducted study in FASS provided evi-
dence of high efficacy of amoxicillin-clavulanate in eosino-
philic plaques and indolent ulcers (QOE 1, SOR A).
However, it is unclear whether the improvement was the
result of eliminating the bacteria from the lesions and/or
immunomodulation, and whether treatment resulted in a
sustained response. In addition, current antimicrobial
treatment guidelines for skin infections (summarised in
Brissot, 2016100) emphasise using topical antimicrobial
therapy over systemic treatment and, where this is nec-
essary, using the lowest tier, most narrow-spectrum drug
possible for the shortest time required to clear the infec-
tion. Long-term therapy in the absence of a bacterial
infection usually is discouraged, and veterinarians are
advised to follow antimicrobial treatment guidelines
established in their country of practice and/or in interna-
tional consensus recommendations. So far, no evidence
has been published supporting the use of antibiotics in
feline asthma (QOE 2, SOR B).
Inhaled lidocaine.
Analysis of evidence
Nebulised lidocaine has received interest as a corticos-
teroid-sparing drug in human asthmatics, reducing airway
resistance and peripheral blood eosinophilia.101,102 It was
evaluated in healthy and experimentally asthmatic cats in
a cross-over study.72 Five healthy and nine experimentally
asthmatic cats received nebulised lidocaine at the dose of
2 mg/kg three times a day for two weeks in a cross-over
design.72
Analysis of efficacy
In healthy cats, lidocaine did not significantly alter BALF
eosinophilia or the concentration of methacholine increas-
ing baseline airway resistance by 200%. There was no
difference in eosinophil percentages in the BALF in asth-
matic cats treated with lidocaine (36  10%) or placebo
(33  6%). However, lidocaine significantly increased the
concentration of methacholine increasing baseline airway
resistance by 200% compared with placebo (10  2 ver-
sus 5  1 mg/mL).72 Adverse effects were not seen with
nebulized lidocaine.
Recommendations
Based on this one study, lidocaine may serve as adjunc-
tive therapy in feline asthmatics with mild beneficial
effects on airflow obstruction (QOE2; SOR B).
Mesenchymal stem cell therapy
Analysis of evidence
Adipose-derived mesenchymal stem cells (MSC) were
evaluated in a small RCT in an experimental feline asthma
model.73 In this pilot study, allogenic adipose-derived
MSCs were administered in five intravenous infusions at
D0, D14, D28, D98 and D130 to four of six cats experi-
mentally sensitized with Bermuda grass while two cats
were treated with placebo.73 BALF eosinophilia was eval-
uated at seven time points over nine months, along with
blood samples to evaluate T-lymphocyte phenotype, total
Bermuda grass allergen-specific lymphocyte proliferation,
IL-10 production from lipopolysaccharide (LPS)-stimulated
whole blood, and numbers of IL-10-producing cells. Addi-
tionally, thoracic computed tomography (CT) in conjunc-
tion with abbreviated pulmonary function testing was
compared to that of healthy cats used as controls.
Analysis of efficacy
Diminished airway hyper-responsiveness was noted in all
MSC-treated compared with the placebo-treated cats at
D133. Lung attenuation and bronchial wall-thickening
scores consistent with decreased airway remodelling
were significantly reduced in MSC-treated versus
untreated asthmatic cats.73
Recommendations
There is limited evidence of mild-to-moderate long-term
efficacy of MSC in the treatment of feline asthma (QOE2;
SOR B).
Discussion
To the best of the authors’ knowledge, this is the first
systematic review of therapeutic interventions for the
feline atopic syndrome, both for FASS and feline asthma.
Such reviews are standard practice in similar human and
canine conditions, where the evidence is used as a base
for treatment guidelines.6,103 The data evaluated in this
review have been used to provide a summary of treat-
ment recommendations (Table 10). Clinicians should note
that these recommendations do not imply that all of the
listed treatments should be used in all patients, nor that
they should be considered in this order.
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Clinical manifestations of FASS are common problems
that decrease the QoL of affected cats and their owners.62
They appear to be chronic conditions that require long-term
management. It is therefore important to eliminate fleas,
Demodex gatoi, and other ectoparasites and endoparasites,
food allergens, bacterial skin infection/pyoderma, yeast
overgrowth and differential diagnoses before making a final
diagnosis. It also is likely that FASS and feline asthma have
a multifaceted aetiology.3 As in cAD and human asthma,
treatments may need to be combined to optimise the out-
come for each cat. Clinical trials usually are designed to
evaluate the efficacy of a single treatment and therefore
may underestimate the efficacy of combination treatment.
Treatment should be tailored to each cat, taking into
account the severity, type and distribution of the lesions,
and stage of the dermatitis and airway disease. It is likely
that most cats will require more potent treatment (e.g.
systemic glucocorticoids, topical and inhaled glucocorti-
coids, ciclosporin or oclacitinib) initially to induce remis-
sion. Treatment can then be tapered and/or switched to
less potent treatments (e.g. ASIT, essential fatty acids
and antihistamines) to maintain the remission.
These treatment recommendations should not be read
as a “diktat”, particularly considering the facts that many
products are not approved for cats, pharmacokinetic data
and dose-finding studies are lacking for most products,
Table 9. Responses to treatment with fatty acids in 37 cases with feline atopic skin syndrome (FASS)
Fatty acids (number
of cats evaluated) Dose
Responses†
References
Type of study QOE36% 6% 58%
Evening primrose oil (n = 7) 0.5 mL/cat once daily 2/7 5/7 Logas and Kunkle 199361
RCT
1
Evening primrose oil/fish oil (n = 14) 0.5 mL/cat once daily 11/14 Harvey 199353
Open study
2
Evening primrose oil (n = 6) 0.25 mL/cat once daily for
12 weeks
Mean overall clinical scores
decreased from 7 to 2.2,
self trauma scores from
50 to 12 and crusted




DVM Derm Cap Liquid (n = 10) 0.2 mL/kg once daily
for 14–44 days
5/10 5/10 Miller and Scott 199339
Case series
2
Mean outcomes 52% 6% 42%‡
QOE quality of evidence, RCT randomised controlled trial.
†
See text for details of the outcome measures.
‡
In one study, only the good-to-excellent responders were mentioned53 and it is unclear if the residual three cats were partial or poor responders
and in order not overestimate the treatment benefits of EFAs we assumed that the residual cases showed a poor response.
Table 10. Summary of treatment recommendations for cats with atopic syndrome
Treatment or intervention Recommendation QOE SOR
Allergen avoidance Limited evidence of moderate efficacy in feline asthma Insufficient evidence in FASS 3 C
Allergen immunotherapy Limited evidence of moderate (feline asthma) to good (FASS) efficacy 2 B




Limited evidence of good efficacy in FASS





Ciclosporin Satisfactory evidence of good efficacy in FASS
Insufficient evidence in feline asthma
1 A
Oclacitinib Limited evidence of good efficacy in FASS





Bronchodilators Recommended for acute asthma attacks
Limited evidence of poor efficacy in feline asthma







Oral H1R-antihistamines Limited evidence of low to moderate efficacy in FASS







Limited evidence of moderate efficacy in FASS (miliary dermatitis)
Limited evidence of moderate efficacy in FASS





Maropitant Limited evidence of good efficacy in FASS





Antibiotics Limited evidence of good efficacy in FASS if there is confirmed infection 2 B
Doxycycline Limited evidence of poor efficacy of doxycycline in asthma 2 B
Inhaled lidocaine Limited evidence of low efficacy in feline asthma 2 B
Stem cell therapy Limited evidence of low to moderate efficacy in feline asthma
Insufficient evidence in FASS
2 B
FAS feline atopic syndrome, FASS feline atopic skin syndrome, QOE quality of evidence, SOR strength of recommendation.
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and safety data beyond the studies discussed here also
are not available for most drugs. Not every treatment will
be effective, tolerated or suitable in every cat. It is up to
the individual clinician to evaluate their patient and dis-
cuss the advantages and disadvantages of each treat-
ment option with the owners. This will include potential
adverse effects, ease-of-administration, and cost as a sin-
gle treatment or in combination. The owners’ preferences
as well as concurrent conditions and medication also will
have to be accounted for. Nevertheless, the treatments
recommended in this review should be considered before
moving to alternatives with less evidence of efficacy and
safety in FASS or feline asthma.
The recommendations in this review were derived lar-
gely from the results of clinical trials reporting statistically
significant changes in various outcome measures. Fol-
lowing best practice, the recommendations were based
on SORT scores7 (Table 1), which are a simple and robust
way of evaluating patient-orientated outcomes. However,
clinicians should note that statistically significant improve-
ments do not necessarily mean that these are clinically
significant (i.e. lead to an acceptable improvement in clini-
cal signs and in the QoL for the patient and owner). More-
over, individual animals may have a better or worse
response than the mean outcome reported in a clinical
trial. In addition, most studies performed on feline
asthma utilised small numbers of cats experimentally
sensitised to HDN, Bermuda grass or A. suum and more
studies are urgently needed assessing treatment options
for naturally occurring feline asthma, as well as evaluating
adverse effects of those therapies with long-term use.
This review highlights the limited evidence for some
treatments in FAS. The analysis of the clinical trials was
variously affected by small group sizes, uncontrolled stud-
ies, retrospective studies, deficient data reporting, and
variable and nonvalidated outcome measures. Compared
to the dog, where a rapidly increasing number of ran-
domised, controlled trials are being published, fewer
studies of lesser quality are found evaluating allergic cats
and more randomised controlled trials are urgently
needed. Wherever possible, the quality of clinical trials
should be improved by designing double-blinded RCTs,
using power calculations to determine adequate treat-
ment cohorts, and using validated outcome measures
(e.g. the SCORFAD84,85 and pVAS82 scales or lung func-
tion studies), similar to those published for dogs with ato-
pic dermatitis104 and in human asthma.105,106 Other
outcome measures relevant to the clinical significance of
therapeutic interventions include a QoL score,86 and glo-
bal scores for efficacy, tolerance and ease-of-administra-
tion. Minimum datasets should include intention-to-treat
data with means or medians and an appropriate measure
of variance (e.g. standard deviation or 95% confidence
intervals). Additional useful outcomes include the propor-
tion of cats reaching certain clinical thresholds (e.g. >50%
and >75% improvements in pruritus and lesion scores or
in lung function). Statistical tests should be appropriate to
the data and, where necessary, advice from a statistician
should be sought during design of the study.
The recommendations in this review are derived from
an evidence-based consensus supporting use of an inter-
vention and do not imply endorsement of specific
therapeutic options or products. Furthermore, these rec-
ommendations do not consider availability or licensing
specifics in individual countries. Clinicians should there-
fore choose individual treatments based on legal and ethi-
cal standards in their own country of practice.
This systemic review of therapeutic interventions has
provided evidence for treatment recommendations in
FAS (Table 10). It is hoped that these will aid clinicians in
designing treatment plans to improve the QoL of their
patients and their owners. The review highlighted short-
falls in the quantity and quality of published data. Clini-
cians are therefore encouraged to publish good quality
clinical trials assessing the efficacy of existing and novel
treatments. Future reviews including such data will
improve the strength and breadth of treatment recom-
mendations for FAS.
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Resume
Contexte – le syndrome atopique felin (FAS) decrit un spectre d’hypersensibilites caracterisees par diver-
ses presentations cliniques comprenant la peau, le systeme digestif et le systeme respiratoire. Parmi ces
atteintes, il y a le syndrome cutane atopique felin (FASS), pour lequel l’hypersensibilite est typiquement
associee a des allergenes environnementaux, bien que l’allergie alimentaire puisse coexister. D’autres
organes (par exemple asthme) peuvent être aussi impliques. En raison de cette grande heterogeneite clini-
que, le diagnostic du FASS peut être un defi.
Objectifs – Un sous-groupe de l’ICADA (International Committee on Allergic Diseases of Animals) a ete
charge de resumer les informations les plus actuelles sur les presentations cliniques du FASS et de deve-
lopper des recommandations de diagnostic.
Methodes – Les citations des bases de donnees en ligne et les resumes des congres internationaux ont
ete recherches pour les publications en lien avec les allergies felines. Ceci a ete combine avec des opinions
d’experts quand necessaire.
Resultats – Un total de 107 publications pertinentes a ete identifie. La compilation de ces donnees a per-
mis le developpement d’une description detaillee des criteres cliniques du FASS et le developpement de
recommandations ciblant une elimination systematique des autres atteintes cutanees avec des caracteris-
tiques cliniques semblables. Alors que les tests allergiques sont frequemment utilises par les dermatolo-
gues pour soutenir le diagnostic clinique du FASS, une revue rapide de ces methodologies a aussi ete
realisee.
Conclusions et importance clinique – De facon semblable a la dermatite atopique canine, le FASS est un
diagnostic clinique base sur la presence compatible avec les signes cliniques et l’exclusion d’autres mala-
dies ayant des criteres cliniques semblables. L’elimination ou l’exclusion des puces/de l’allergie aux puces,
d’autres parasites, des infections et de l’allergie alimentaire est necessaire avant d’etablir un diagnostic de
FASS.
Resumen
Introduccion – el sındrome atopico felino (FAS) describe un espectro de trastornos de hipersensibilidad
caracterizados por presentaciones clınicas muy diversas que incluyen la piel, los sistemas gastrointestinal y
respiratorio. Entre estos trastornos se encuentra el sındrome de piel atopica felina (FASS), en el que la
hipersensibilidad se asocia tıpicamente con alergenos ambientales, aunque la alergia alimentaria puede
coexistir. Tambien puede producirse la afectacion de otros sistemas organicos (por ejemplo asma). Debido
a su presentacion clınica altamente heterogenea, el diagnostico de FASS puede ser difıcil.
Objetivos – Se encomendo a un subgrupo del Comite Internacional sobre Enfermedades Alergicas de los
Animales (ICADA) que resumiera la informacion mas actual sobre las presentaciones clınicas de FASS y
que desarrollara pautas de diagnostico recomendadas.
Metodos – Se realizaron busquedas en la red de bases de datos de referencias y resumenes de reuniones
internacionales relacionadas con alergias felinas. Estos se combinaron con la opinion de expertos cuando
fue necesario.
Resultados – Se identificaron un total de 107 publicaciones relevantes para esta revision. La recopilacion
de estos datos permitio el desarrollo de una descripcion detallada de las caracterısticas clınicas de FASS y
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el desarrollo de pautas centradas en la eliminacion sistematica de otras afecciones de la piel con carac-
terısticas clınicas similares. Dado que los dermatologos utilizan con frecuencia las pruebas de alergia para
respaldar un diagnostico clınico de FASS, tambien se realizo una breve revision de estas metodologıas.
Conclusiones e importancia clınica – De manera similar a la dermatitis atopica en perros, FASS es un
diagnostico clınico basado en la presencia de signos clınicos compatibles y la exclusion de otras enferme-
dades con caracterısticas clınicas similares. La eliminacion o exclusion de pulgas/alergia a pulgas, otros
parasitos, infecciones y alergia alimentaria es necesaria antes de llegar a un diagnostico de FASS.
Zusammenfassung
Hintergrund – Das Feline atopische Syndrom (FAS) beschreibt ein Spektrum von Hypersensibilit€atserkran-
kungen, die durch sehr unterschiedliche klinische Pr€asentationen auf der Haut, dem Gastrointestinaltrakt
und dem Respirationstrakt charakterisiert sind. Unter diesen Erkrankungen ist auch das Feline Atopische
Haut Syndrom (FASS), bei dem eine Hypersensibilit€at typisch mit Umweltallergenen in Zusammenhang
steht, obwohl eine Futterallergie gleichzeitig bestehen k€onnte. Es k€onnen auch andere Organsysteme mit
involviert sein (z.B. Asthma). Aufgrund der hochgradig heterogenen klinischen Pr€asentation kann die Dia-
gnose der FASS eine Herausforderung darstellen.
Ziele – Eine Untergruppe des International Committee on Allergic Diseases of Animals (ICADA) sollte die
g€angigste Information €uber die klinischen Pr€asentationen vom FASS zusammenfassen und diagnostische
Richtlinien entwerfen.
Methoden – Es wurden Online Literaturstellen und Abstracts von internationalen Treffen auf Publikationen
€uber Allergien der Katze durchsucht. Diese wurden, wenn n€otig, mit einer Expertenmeinung kombiniert.
Ergebnisse – Es wurden insgesamt 107 Publikationen, die f€ur dieses Thema relevant waren, identifiziert.
Eine Erfassung dieser Daten erlaubte die Entwicklung einer detaillierten Beschreibung der klinischen Merk-
male des FASS und die Entwicklung von Richtlinien, die sich auf die systematische Eliminierung von ande-
ren Hauterkrankungen mit €ahnlichen klinischen Charakteristika konzentrieren. Da Allergietests von
Dermatologen h€aufig verwendet werden, um eine klinische Diagnose des FASS zu untermauern, wurde
eine kurze Review dieser Methoden durchgef€uhrt.
Schlussfolgerungen und klinische Bedeutung – In einer €ahnlichen Weise wie bei der atopischen Derma-
titis der Hunde, ist das FASS eine klinische Diagnose, die auf dem Vorkommen von kompatiblen klinischen
Zeichen und einem Ausschluss anderer Krankheiten mit €ahnlichen klinischen Merkmalen beruht. Eine Eli-
minierung von Fl€ohen/Flohspeichelallergie, anderer Parasiten, Infektionen und Futterallergie sind zwingend
notwendig, bevor die Diagnose einer FASS getroffen werden kann.
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结论和临床重要性 – 与犬特应性皮炎相似, FASS的临床诊断是基于相符的临床症状,并排除具有相似临床特
征的其他疾病。在确诊FASS之前, 必须消除或排除跳蚤/跳蚤过敏、其他寄生虫、感染和食物过敏。
Resumo
Contexto – A sındrome atopica felina (SAF) descreve um espectro de disturbios de hipersensibilidade
caracterizados por uma apresentac~ao clınica altamente diversa, incluindo a pele, sistema gastrointestinal e
respiratorio. Dentre esses disturbios esta a sındrome atopica cutânea felina (FASS, feline atopic skin syn-
drome), na qual hipersensibilidade e tipicamente associada a alergenos ambientais, apesar de alimentos
poderem coexistir. O envolvimento de outros sistemas (ex: asma) pode tambem ocorrer. Devido a essa
apresentac~ao clınica altamente heterogênea, o diagnostico da FASS pode ser desafiador.
Objetivos – Um subgrupo do International Committee on Allergic Diseases of Animals (ICADA) foi desig-
nado a sintetizar as informac~oes mais recentes sobre as apresentac~oes clınicas da FASS, e a desenvolver
diretrizes diagnosticas.
Metodos – Bancos de dados de citac~oes online e resumos de congressos internacionais foram utilizados
para buscar publicac~oes relacionadas a alergias em felinos. Quando necessario, estes foram combinados
com as opini~oes dos experts.
Resultados – Um total de 107 publicac~oes relevantes a essa revis~ao foram identificados. A compilac~ao
desses dados permitiu o desenvolvimento de uma descric~ao detalhada das caracterısticas clınicas da FASS
e o desenvolvimento de diretrizes focando a eliminac~ao sistematica de outras dermatopatias com carac-
terısticas similares. Como os testes alergicos s~ao frequentemente utilizados por dermatologistas para
apoiar o diagnostico clınico de FASS, uma rapida revis~ao destas metodologias foi realizada.
Conclus~oes e importância clınica – Semelhante a dermatite atopica em c~aes, a FASS e um diagnostico
clınico baseado nos sinais clınicos compatıveis e exclus~ao de outras doencas com caracterısticas clınicas
similares. A eliminac~ao de pulgas/alergia a picada de pulgas, outros parasitas, infecc~oes e alergia alimentar
e mandatoria antes de se fechar o diagnostico da FASS.
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